Perimenopause is now pulling menopause care into the mainstream, but the bottleneck in UK clinics is still access: who gets a confident prescription, who gets told to wait, and who gets moved down a different pathway when bleeding starts on systemic HRT. NICE’s NG23 was last reviewed on 15 April 2026, and its April 2026 change added specific advice on unscheduled vaginal bleeding while taking systemic HRT. That is the kind of update that changes what happens in a GP surgery tomorrow, not the kind of headline that automatically improves access across the NHS.
NICE has widened the frame beyond HRT
The current NICE guideline on menopause covers identifying and managing menopause, including in people with premature ovarian insufficiency. Its November 2024 update added or refreshed recommendations on cognitive behavioural therapy for menopausal symptoms and on managing genitourinary symptoms, which makes clear that treatment is broader than oestrogen alone. The British Menopause Society has also pointed clinicians to the updated NICE guideline Menopause: Identification and Management, saying it was published in November 2024.
The April 2026 amendment matters because it aligns advice on unscheduled vaginal bleeding while taking systemic HRT with NICE’s suspected-cancer guidance. NICE amended recommendation 1.8.4 and added 1.8.5 for that purpose. In practice, that means bleeding on systemic HRT is not something to shrug off or normalise away. If you have unscheduled vaginal bleeding while using systemic HRT, you should speak to your GP promptly.
The real pressure point is prescribing confidence
The latest debate around menopause care is not about whether HRT exists. It is about how much judgment GPs are expected to use, and how much support they get when symptoms, comorbidities and patient concerns collide. In BMJ commentary published on 26 June 2025, Mary Ann Lumsden and Sarah Hardman said NICE menopause guidance still lacks nuance and that treatment requires a personalised approach.
That argument is echoed in specialist commentary around the updated guideline. In a November 2024 YouTube summary of NICE’s update, Dr Nighat Arif called it “a step in the right direction” and said more guidance was still needed on systemic HRT for people affected by cancer, endometriosis, PCOS, ADHD and neurodegenerative disease. That list matters because it shows where routine perimenopause care becomes complex, and where clinician confidence can make the difference between treatment and delay.
The new BMS guidance on unscheduled bleeding on HRT also shows how far menopause management now reaches beyond one specialty. The joint guideline was produced with the British Society of Gynaecological Endoscopy, the British Gynaecological Cancer Society, the Faculty of Sexual & Reproductive Healthcare, Getting It Right First Time, the Royal College of General Practitioners and the Royal College of Obstetricians & Gynaecologists. That cross-society footprint reflects the reality in UK clinics: bleeding on HRT sits across primary care, gynaecology and cancer pathways at the same time.
Access is uneven, and patients feel it
The clearest evidence that access is not equal comes from a 2025 British Journal of General Practice qualitative study on women’s experiences of accessing equitable menopause care in the contemporary NHS. The PubMed summary says menopause may be particularly disruptive to modern women and that women are often dissatisfied with the options available. That is not a prescribing algorithm, but it is a warning sign that the pathway itself is frustrating patients before treatment even starts.
A separate University of Birmingham study on GP clinician experiences in diverse communities, with an early online date of 6 June 2025, points to the other half of the problem: clinicians themselves see menopause care as difficult to deliver fairly across communities. That is where postcode variation shows up in real life, not as a neat map but as uneven confidence in recognising perimenopause, discussing HRT, and escalating complex cases. The result is that access can depend as much on the practice you reach as on the symptoms you present with.
A 2025 BMJ piece went further, arguing that menopause care is neglected and inequitable and that sustained research effort and investment are needed to reduce those gaps. Taken together, the studies show a system that is asking GPs to do more, across more patient groups, without making the pathway more uniform.
Supply shocks and the private market are pulling in different directions
The HRT market has already been tested by shortages, and those shortages have shaped policy before. The Department of Health and Social Care previously issued Serious Shortage Protocols to limit dispensing of three HRT products to three months’ supply, an intervention designed to keep women on treatment when supplies were under pressure. That history still matters because it showed how quickly access problems can become national policy problems.
Private providers have stepped into that gap by selling speed. One London private GP advertises same-day appointments and consultations from £125, while other private menopause clinic pages market faster access and specialist care. Those claims are not the same as NHS access, and they do not mean a private route solves the underlying bottlenecks. They do show where the commercial pull is strongest: in the wait between asking for help and getting seen.
For the NHS, newer treatment options only improve care if they fit existing pathways. That means being simple enough for primary care, clear enough for unscheduled bleeding decisions, and credible enough for women who have been put off by older hormone safety debates. If a treatment mainly benefits people who can pay for speed, it is not yet solving the access problem that perimenopause demand has exposed.
Menopause is now a workplace and productivity issue too
The policy background is wider than medicine. The House of Commons Women and Equalities Committee published its report Menopause and the workplace on 28 July 2022 and called for government action on workplace support. GOV.UK’s Menopause in the Workplace Literature Review and the progress report Shattering the Silence about Menopause show Whitehall treating menopause as an employment and economic issue, not just a clinical one.
That matters because work loss, absence and reduced productivity are part of why employers and occupational-health teams are now in the market. Menopause care is no longer only about symptom relief in a consulting room. It is about whether people can stay in work, get assessed quickly and move through a system that is still patchy for complex cases.
What changes patient care now
The headline shift is not a flood of brand-new treatments. It is a more explicit set of rules around bleeding, a broader NICE frame that includes CBT and genitourinary symptoms, and a stronger push for personalised care in difficult cases. The bottlenecks that still matter most are GP prescribing confidence, uneven local access, specialist waits that push women towards private care, and the practical disruption caused by supply problems.
The market will reward products and services that do one thing well: make it easier for a woman in perimenopause to get the right treatment through the pathway she can actually use. Until that happens, the biggest change in UK menopause care is not hype about the HRT market. It is the slow, uneven work of making routine care less arbitrary.